TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC ...

Source: Journal of Experimental and Clinical Cancer Research - March 9, 2024 Category: Cancer & Oncology Authors: Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D ’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella St Tags: Research Source Type: research